Copyright © Inderes 2011 - present. All rights reserved.

Oriola

1.01 EUR

-2.52 %

7,755 following
Corporate customer

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-2.52 %
-13.72 %
-12.52 %
-8.04 %
-13.28 %
-10.66 %
-34.93 %
-49.95 %
-45.31 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
186.44M EUR
Turnover
70.84K EUR
P/E (adj.) (26e)
12.22
EV/EBIT (adj.) (26e)
1.69
P/B (26e)
1.79
EV/S (26e)
0.02
Dividend yield-% (26e)
3.98 %
Coverage
Recommendation
Accumulate
Target price
1.20 EUR
Updated
25.02.2026
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 14.01.2026

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.3
2026

General meeting '26

26.3
2026

Annual dividend

29.4
2026

Interim report Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Third party research

Oriola: Awaiting news on strategy review - Evli

Oriola’s Q4 was overall rather good, with double-digit growth exceeding expectations while profitability in Wholesale remained soft. For now, all eyes are on news from the strategy review and Capital Markets Day in May.

Oriola

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Oriola: Growth pace remains solid - Evli

Oriola posted overall good figures in Q4. Net sales and invoicing growth was in the double-digits, and the pace exceeded our expectations. The adj. EBITDA of EUR 9.9m fell slightly short of our EUR 10.3m expectations, as the profitability in the Wholesale...

Oriola
Third party research

Oriola: Expecting a busy year ahead - Evli

We expect continued good growth in Q4 and fairly flat margin development q/q. 2026 is looking to be a busy year, but if one should be excited about the actions to be taken still remains to be seen.

Oriola
Third party research

Oriola: Earnings turning positive - Evli

Oriola posted good Q3 results, with a key positive the faster recovery than we had expected recovery of profitability in the Wholesale segment. With good development across the board, earnings also turned positive. We raise our target price to EUR 1....

Oriola
Third party research

Oriola: Good development across the board - Evli

Oriola posted good figures in Q3. Net sales growth was nearly in the double-digits, while the adj. EBITDA of EUR 9.6m exceeded our EUR 9.1m expectations. Profitability was aided by faster than anticipated profitability recovery of the Wholesale-segment...

Oriola
Forum discussions
NOT LIKE THIS! That was some tough reading, as the whole report was pure bullshit bingo. The dividend was halved, and Kronans is still a complete farce. The ERP project apparently takes forever and has failed completely; AI was also mentioned in the report, because well, I don’t ...
2/25/2026, 9:06 AM
by Trivial
17
This post is primarily intended for Oriola’s communications and finance departments as a comment for improving Oriola’s financial reporting and for the Capital Markets Day. The biggest problem with Oriola’s financial reporting is that true and fair information regarding the JV company...
1/19/2026, 2:10 PM
by Aktivisti26
17
Inderes Oriola Oyj:n tilinpäätöstiedote 1.1.- 31.12.2025 - Inderes Oriola Oyj:n pörssitiedote 25.2.2026 klo 8.30Oriola Oyj:n tilinpäätöstiedote 1.1.- 31.12.2025Oikaistun käyttökatteen ja strategisten tavoitteiden vakaa kehitysLoka-joulukuun 2025 pääkohdat Laskutus... October–December...
2/25/2026, 6:34 AM
by kimsku
10
Iikka interviewed Oriola’s CEO Katarina Gabrielson regarding the Q4 results Inderes Oriola Q4'25: Double‑digit revenue growth - Inderes Aika: 25.02.2026 klo 14.26 Oriola’s revenue grew 14% in Q4. Oriola’s adjusted EBITDA improved to 9.9 MEUR from 9.4 MEUR in the comparison period...
2/25/2026, 3:02 PM
by Sijoittaja-alokas
7
The bot interpreted this somewhat confusing reporting quite well, but here’s my quick comment as well Inderes Oriola Q4’25 -pikakommentti: Omat toiminnot karkeasti odotuksiin, Kronansista... Oriolan omien toimintojen tulos osui suunnilleen odotuksiimme ja ohjeistus tulosparannuksesta...
2/25/2026, 7:32 AM
by Rauli_Juva
7
The most sensible thing would be to freeze dividends completely for at least a couple of years. It’s idiotic to pay out dividends and then beg for the money back shortly after in a share issue. Naturally, via a directed issue at a discount, just to maximize the retail investors’ ...
1/14/2026, 3:15 PM
by tj_hodl
7
Of course the ERP isn’t ready yet, as it was stated at the beginning of 2024 that the project would last until 2027. However, it was mentioned on the call that it hasn’t been decided yet whether the old system will be used first in the new distribution center to be built in Finland...
2/25/2026, 10:22 AM
by Rauli_Juva
6
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.